Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation är ett kutant tillstånd som kännetecknas av ökat pigment i huden efter inflammation i huden. Postinflammatory hyperpigmentation kan orsakas av långvarig solexponering, inflammation eller andra hudskador, inklusive sådana som är relaterade till akne. Människor med mörkare hudtoner är vanligtvis mer benägna att hyperpigmentera med överdriven solexponering.
☆ I Stiftung Warentest-resultaten 2022 från Tyskland var konsumentnöjdheten med ModelDerm bara något lägre än med betalda telemedicinkonsultationer.
References
Postinflammatory hyperpigmentation (PIH) är ett frekvent hudproblem som uppstår efter hudinflammation eller skada. Det brukar hålla länge och är värre hos personer med mörkare hudtoner (Fitzpatrick skin types III–VI) . Även om det ofta blir bättre av sig själv kan detta ta ett tag, så behandling behövs ofta under lång tid. Att kombinera olika behandlingar fungerar bäst.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation är en vanlig följd av hudinflammation. Det tenderar att påverka mörkhyade individer mer allvarligt och oftare. Studier visar att problem som postinflammatory hyperpigmentation är bland de främsta anledningarna till att personer med mörkare hudtoner söker hudvård. Tidig behandling är avgörande för att lösa postinflammatory hyperpigmentation och börjar vanligtvis med att hantera det initiala inflammatoriska tillståndet. Den första behandlingen innebär vanligtvis att man använder topikala medel som gör huden ljusare tillsammans med solskyddsmedel. Dessa medel, som hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , kan effektivt minska överdriven pigmentering. Dessutom används retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy också som depigmenteringsmedel, med nya behandlingar som dyker upp. Medan topikala behandlingar vanligtvis är effektiva för hyperpigmentering på ytnivå, kan procedurer (laser, chemical peel) vara nödvändiga för envisa fall. Det är viktigt att vara försiktig med dessa behandlingar för att undvika irritation och förvärring av postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
